Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 20…

Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of long-term ...
KTLA

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
Drug Store News

Sanofi to acquire Blueprint Medicines for about $9.1B

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline. Paul Hudson, CEO of Sanofi said, "The proposed acquisition of Blueprint Medicines ...
Seeking Alpha

Press Release: Sanofi completes acquisition of Blueprint Medicines

Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, ...
KELOLAND News

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...
The Business Journals

Sanofi to buy Blueprint Medicines for $9.1B

Kate Haviland is CEO of Blueprint Medicines. From the Boston Business Journal. Sanofi is acquiring Blueprint Medicines Corp. and its rare immunology disease treatment, which is already approved in the ...